期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Liver cancer:Targeted future options 被引量:7
1
作者 Andreas Pircher Michael Medinger joachim drevs 《World Journal of Hepatology》 CAS 2011年第2期38-44,共7页
Hepatocellular carcinoma(HCC)has a poor prognosis an d systemic chemotherapies have disappointing results.The increasing knowledge of the molecular biolog y of HCC has resulted in novel targets,with the vascular endot... Hepatocellular carcinoma(HCC)has a poor prognosis an d systemic chemotherapies have disappointing results.The increasing knowledge of the molecular biolog y of HCC has resulted in novel targets,with the vascular endothelial growth factor and epidermal growth factor receptor(EGFR)-related pathways being of special interest.New blood vessel formation(angiogenesis)is essential for the growth of solid tumors.Anti-angiogenic strategies have become an important therapeutic modality for solid tumors.Several agents targeting angiogenesis-related pathways have entered clinical trials or have been already approved for the treatment of solid tumors.These include monoclonal antibodies,receptor tyrosine kinase inhibitors and immunomodulatory drugs.HCC is a highly vascular tumor,and angiogenesis is be-lieved to play an important role in its development and progression.This review summarizes recent advances in the basic understanding of the role of angiogenesis in HCC as well as clinical trials with novel therapeutic approaches targeting angiogenesis and EGFR-related pathways. 展开更多
关键词 Angiogenesis EPIDERMAL GROWTH FACTOR receptor Hepatocellular carcinoma TARGETED therapy Vascular ENDOTHELIAL GROWTH FACTOR
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部